Download PDF
Der Nuklearmediziner 2007; 30(3): 180-194
DOI: 10.1055/s-2007-981212
CME Beitrag

© Georg Thieme Verlag Stuttgart · New York

Nuklearmedizinische Verfahren in der Diagnostik der Demenzerkrankungen

Nuclear Medicine Imaging in the Diagnosis of DementiasA. Drzezga1
  • 1Nuklearmedizinische Klinik, Klinikum rechts der Isar, Technische Universität, München
Further Information

Publication History

Publication Date:
28 February 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die aufgrund der demografischen Entwicklung zunehmende Zahl von Demenzerkrankungen stellt ein zunehmendes medizinisches und soziökonomisches Problem dar. Insbesondere vor dem Hintergrund neuer und in Entwicklung befindlicher Therapieoptionen wird eine sichere Früh- und Differenzialdiagnostik zunehmend an Bedeutung gewinnen, um in einem möglichst frühen Krankheitsstadium geeignete Therapien einzuleiten. Die funktionelle Bildgebung mittels PET und SPECT kann hierzu einen wichtigen Beitrag leisten; so stellt insbesondere die [18F]FDG-PET eine höchst empfindliche Methode zur Frühdiagnose neurodegenerativer Demenzerkrankungen dar. Der vorliegende Artikel soll einen Überblick über den aktuellen Stand der nuklearmedizinischen Demenzdiagnostik geben und die pathognomonischen Befundmuster und ihre Differenzialdiagnosen aufzeigen.

Abstract

Due to the current demographic development, the increasing prevalence of dementias represents a serious medical and economical issue. With regard to new and upcoming treatment options, based on this background, the reliable early and differential diagnosis will be of increasing importance, in order not to delay suitable therapies. Functional brain imaging by means of PET and SPECT can substantially contribute to this diagnostic challenge, and PET using [18F]FDG could be shown to be a highly sensitive method for the early diagnosis of neurodegenerative dementias. The purpose of this article is to give a survey on the current state of nuclear medicine imaging of dementias and to present the typical brain metabolic findings and their differential diagnoses.

Schlüsselwörter

Demenz - Alzheimer - Lewy Bodies - PET - SPECT

Key words

dementia - Alzheimer - Lewy Bodies - PET - SPECT

Literatur

  • 1 Forstl H, Kurz A. Clinical features of Alzheimer's disease.  Eur Arch Psychiatry Clin Neurosci. 1999;  249 288-290
    CrossrefPubMedGoogle Scholar
  • 2 McKhann G, Drachman D, Folstein M. et al . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.  Neurology. 1984;  34 939-944
    CrossrefPubMedGoogle Scholar
  • 3 Hebert L E, Scherr P A, Bienias J L. et al . Alzheimer disease in the US population: prevalence estimates using the 2000 census.  Arch Neurol. 2003;  60 1119-1122
    CrossrefPubMedGoogle Scholar
  • 4 Alafuzoff I. The pathology of dementias: an overview.  Acta Neurol Scand Suppl. 1992;  139 8-15
    PubMedGoogle Scholar
  • 5 Gotz J, Ittner L M, Schonrock N. Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?.  Med J Aust. 2006;  185 381-384
    PubMedGoogle Scholar
  • 6 Olsen C E, Poulsen H D, Lublin H K. Drug therapy of dementia in elderly patients. A review.  Nord J Psychiatry. 2005;  59 71-77
    CrossrefPubMedGoogle Scholar
  • 7 Kaufer D I. Pharmacologic therapy of dementia with Lewy bodies.  J Geriatr Psychiatry Neurol. 2002;  15 224-232
    PubMedGoogle Scholar
  • 8 Herholz K, Schopphoff H, Schmidt M. et al . Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease.  J Nucl Med. 2002;  43 21-26
    PubMedGoogle Scholar
  • 9 Silverman D H. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.  J Nucl Med. 2004;  45 594-607
    PubMedGoogle Scholar
  • 10 Phelps M E, Schelbert H R, Mazziotta J C. Positron computed tomography for studies of myocardial and cerebral function.  Ann Intern Med. 1983;  98 339-359
    PubMedGoogle Scholar
  • 11 Magistretti P J, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging.  Philos Trans R Soc Lond B Biol Sci. 1999;  354 1155-1163
    CrossrefPubMedGoogle Scholar
  • 12 Rocher A B, Chapon F, Blaizot X. et al . Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons.  Neuroimage. 2003;  20 1894-1898
    CrossrefPubMedGoogle Scholar
  • 13 Bartenstein P, Minoshima S, Hirsch C. et al . Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT.  J Nucl Med. 1997;  38 1095-1101
    PubMedGoogle Scholar
  • 14 Drzezga A, Grimmer T, Riemenschneider M. et al . Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.  J Nucl Med. 2005;  46 1625-1632
    PubMedGoogle Scholar
  • 15 Minoshima S, Frey K A, Koeppe R A. et al . A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.  J Nucl Med. 1995;  36 1238-1248
    PubMedGoogle Scholar
  • 16 Herholz K. PET studies in dementia.  Ann Nucl Med. 2003;  17 79-89
    CrossrefPubMedGoogle Scholar
  • 17 Petkova A T, Ishii Y, Balbach J J. et al . A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR.  Proc Natl Acad Sci USA. 2002;  99 16742-16747
    CrossrefPubMedGoogle Scholar
  • 18 Petersen R C, Smith G E, Waring S C. et al . Mild cognitive impairment: clinical characterization and outcome.  Arch Neurol. 1999;  56 303-308
    CrossrefPubMedGoogle Scholar
  • 19 Herholz K. FDG PET and differential diagnosis of dementia.  Alzheimer Dis Assoc Disord. 1995;  9 6-16
    PubMedGoogle Scholar
  • 20 Minoshima S. Imaging Alzheimer's disease: clinical applications.  Neuroimaging Clin N Am. 2003;  13 769-780
    CrossrefPubMedGoogle Scholar
  • 21 Silverman D H, Small G W, Chang C Y. et al . Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.  Jama. 2001;  286 2120-2127
    CrossrefPubMedGoogle Scholar
  • 22 Mazziotta J C, Frackowiak R S, Phelps M E. The use of positron emission tomography in the clinical assessment of dementia.  Semin Nucl Med. 1992;  22 233-246
    CrossrefPubMedGoogle Scholar
  • 23 Salmon E, Sadzot B, Maquet P. et al . Differential diagnosis of Alzheimer's disease with PET.  J Nucl Med. 1994;  35 391-398
    PubMedGoogle Scholar
  • 24 Minoshima S, Giordani B, Berent S. et al . Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.  Ann Neurol. 1997;  42 85-94
    CrossrefPubMedGoogle Scholar
  • 25 Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD.  Eur J Nucl Med Mol Imaging. 2005;  32 486-510
    CrossrefPubMedGoogle Scholar
  • 26 Reiman E M, Caselli R J, Yun L S. et al . Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.  N Engl J Med. 1996;  334 752-758
    CrossrefPubMedGoogle Scholar
  • 27 Zamrini E, De Santi S, Tolar M. Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease.  Neurobiol Aging. 2004;  25 685-691
    CrossrefPubMedGoogle Scholar
  • 28 Petrella J R, Coleman R E, Doraiswamy P M. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future.  Radiology. 2003;  226 315-336
    CrossrefPubMedGoogle Scholar
  • 29 Lim A, Tsuang D, Kukull W. et al . Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series.  J Am Geriatr Soc. 1999;  47 564-569
    PubMedGoogle Scholar
  • 30 Silverman D H, Gambhir S S, Huang H W. et al . Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits.  J Nucl Med. 2002;  43 253-266
    PubMedGoogle Scholar
  • 31 Silverman D H, Cummings J L, Small G W. et al . Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment.  Mol Imaging Biol. 2002;  4 283-293
    PubMedGoogle Scholar
  • 32 Knopman D S, DeKosky S T, Cummings J L. et al . Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2001;  56 1143-1153
    CrossrefPubMedGoogle Scholar
  • 33 Drzezga A, Lautenschlager N, Siebner H. et al . Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.  Eur J Nucl Med Mol Imaging. 2003;  30 1104-1113
    CrossrefPubMedGoogle Scholar
  • 34 Alexander G E, Chen K, Pietrini P. et al . Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.  Am J Psychiatry. 2002;  159 738-745
    CrossrefPubMedGoogle Scholar
  • 35 Stefanova E, Wall A, Almkvist O. et al . Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.  J Neural Transm. 2006;  113 205-218
    PubMedGoogle Scholar
  • 36 Kuhl D E, Koeppe R A, Minoshima S. et al . In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease.  Neurology. 1999;  52 691-699
    PubMedGoogle Scholar
  • 37 Selkoe D J. Alzheimer's disease is a synaptic failure.  Science. 2002;  298 789-791
    CrossrefPubMedGoogle Scholar
  • 38 Price J L, Morris J C. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease.  Ann Neurol. 1999;  45 358-368
    CrossrefPubMedGoogle Scholar
  • 39 Klunk W E, Engler H, Nordberg A. et al . Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.  Ann Neurol. 2004;  55 306-319
    CrossrefPubMedGoogle Scholar
  • 40 Price J C, Klunk W E, Lopresti B J. et al . Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.  J Cereb Blood Flow Metab. 2005;  25 1528-1547
    CrossrefPubMedGoogle Scholar
  • 41 Lopresti B J, Klunk W E, Mathis C A. et al . Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.  J Nucl Med. 2005;  46 1959-1972
    PubMedGoogle Scholar
  • 42 Mintun M A, Larossa G N, Sheline Y I. et al . [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.  Neurology. 2006;  67 446-452
    CrossrefPubMedGoogle Scholar
  • 43 Neary D, Snowden J S, Gustafson L. et al . Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.  Neurology. 1998;  51 1546-1554
    CrossrefPubMedGoogle Scholar
  • 44 Diehl J, Grimmer T, Drzezga A. et al . Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study.  Neurobiol Aging. 2004;  25 1051-1056
    CrossrefPubMedGoogle Scholar
  • 45 Ishii K. Clinical application of positron emission tomography for diagnosis of dementia.  Ann Nucl Med. 2002;  16 515-525
    CrossrefPubMedGoogle Scholar
  • 46 Drzezga A, Grimmer T, Siebner H. et al . Prominent hypometabolism of the right temporoparietal and frontal cortex in two left-handed patients with primary progressive aphasia.  J Neurol. 2002;  249 1263-1267
    CrossrefPubMedGoogle Scholar
  • 47 Diehl-Schmid J, Grimmer T, Drzezga A. et al . Longitudinal changes of cerebral glucose metabolism in semantic dementia.  Dement Geriatr Cogn Disord. 2006;  22 346-351
    CrossrefPubMedGoogle Scholar
  • 48 Nestor P J, Fryer T D, Hodges J R. Declarative memory impairments in Alzheimer's disease and semantic dementia.  Neuroimage. 2006;  30 1010-1020
    CrossrefPubMedGoogle Scholar
  • 49 McKeith I G, Dickson D W, Lowe J. et al . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.  Neurology. 2005;  65 1863-1872
    CrossrefPubMedGoogle Scholar
  • 50 Vander Borght T, Minoshima S, Giordani B. et al . Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.  J Nucl Med. 1997;  38 797-802
    PubMedGoogle Scholar
  • 51 Mahapatra R K, Edwards M J, Schott J M, Bhatia K P. Corticobasal degeneration.  Lancet Neurol. 2004;  3 736-743
    CrossrefPubMedGoogle Scholar
  • 52 McKeith I, O'Brien J, Walker Z. et al . Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.  Lancet Neurol. 2007;  6 305-313
    CrossrefPubMedGoogle Scholar
  • 53 Plotkin M, Amthauer H, Klaffke S. et al . Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients.  J Neural Transm. 2005;  112 677-692
    CrossrefPubMedGoogle Scholar
  • 54 Videbech P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review.  Acta Psychiatr Scand. 2000;  101 11-20
    PubMedGoogle Scholar
  • 55 Sadowski M, Pankiewicz J, Scholtzova H. et al . Links between the pathology of Alzheimer's disease and vascular dementia.  Neurochem Res. 2004;  29 1257-1266
    CrossrefPubMedGoogle Scholar
  • 56 Kerrouche N, Herholz K, Mielke R. et al . 18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis.  J Cereb Blood Flow Metab. 2006;  26 1213-1221
    PubMedGoogle Scholar
  • 57 Sabri O, Schneider R, Buell U. Comparison of PET, SPET, neuropsychological and morphological findings in vascular dementia.  Eur J Nucl Med. 1997;  24 348-349
    CrossrefPubMedGoogle Scholar

PD Dr. A. Drzezga

Nuklearmedizinische Klinik · Klinikum rechts der Isar der Technischen Universität München

Ismaninger Str. 22

81675 München

Phone: +49/89/41 40 29 71

Fax: +49/89/41 40 48 41

Email: a.drzezga@lrz.tu-muenchen.de

      >